Company Overview
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.29.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +137.11% |
| 6 Months: | +57.72% |
| 3 Months: | +15.41% |
| 1 Month: | +32.71% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.98 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | JBIO Jade Biosciences, Inc. R2K | 21.34 | -8.11 | $1.30B | 0.00% | -34.07% | -38.32% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | -1.62M | -2.24M | -2.78M | -5.77M | -6.20M | -11.02M | -12.21M | -14.15M | -17.64M | -20.34M | -21.37M | -24.62M | -26.16M | -15.55M | -23.38M | -27.78M | -27.40M | -43.45M |
| Net Income | -1.44M | -2.20M | -2.31M | -2.78M | -5.78M | -6.18M | -10.91M | -11.99M | -13.59M | -16.52M | -19.02M | -19.56M | -23.19M | -24.77M | -16.87M | -38.17M | -32.13M | -25.18M | -40.37M |
| Diluted EPS | - | - | - | - | - | -0.26 | -0.45 | -0.49 | -0.56 | -0.67 | -0.76 | -0.71 | -0.83 | -0.86 | -5.35 | -12.10 | -0.86 | -0.48 | -0.57 |
| R&D Expense | - | 1.47M | 1.97M | 2.20M | 4.33M | 3.42M | 7.25M | 8.36M | 10.78M | 13.49M | 16.03M | 16.88M | 20.08M | 21.25M | 13.66M | 20.02M | 22.55M | 22.01M | 36.05M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -8.89M | -23.02M | -53.24M | -81.41M | -74.60M | -113.54M |
| Net Income | -9.61M | -22.96M | -51.51M | -75.52M | -69.63M | -127.41M |
| Diluted EPS | - | -1.87 | -2.10 | -2.87 | -2.44 | -3.19 |
| R&D Expense | 7.94M | 14.99M | 38.62M | 64.22M | 53.19M | 93.12M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Jun 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 4.71M | 175.36M | 135.30M | 127.42M | - | 72.80M | 349.78M |
| Total Equity | -3.64M | -13.34M | 172.42M | 126.74M | 109.46M | 1.00K | -46.80M | 332.52M |
| Cash & Equivalents | - | 4.57M | 54.20M | 22.40M | 23.49M | - | 69.39M | 88.44M |
| Total Liabilities | - | 1.77M | 2.94M | 8.56M | 17.96M | - | 119.60M | 17.26M |
| Current Liabilities | - | 1.77M | 2.55M | 7.78M | 17.64M | - | 12.00M | 16.54M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.86M | -27.40M | -39.12M | -56.78M | -71.20M | -94.69M |
| Investing Cash Flow | - | -113.43M | 6.93M | 11.88M | 56.03M | -247.01M |
| Financing Cash Flow | 8.92M | 190.46M | 396.00K | 46.00M | 25.43M | 360.77M |
| Capital Expenditure | - | -181.00K | -195.00K | -142.00K | - | -196.00K |
| Free Cash Flow | - | -27.58M | -39.32M | -56.92M | - | -94.89M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 72.0% | -13.3% | -40.6% | -69.0% | 148.8% | -38.3% |
| ROCE % | -302.2% | -13.3% | -41.7% | -74.2% | -122.7% | -34.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.35% | 7.09M | $152.34M |
| 2 | Fairmount Funds Management LLC | 9.23% | 4.55M | $97.90M |
| 3 | RA Capital Management, L.P. | 7.44% | 3.67M | $78.93M |
| 4 | Bellevue Group AG | 7.09% | 3.50M | $75.28M |
| 5 | Venrock Adviser, LLC | 6.52% | 3.22M | $69.24M |
| 6 | Janus Henderson Group PLC | 6.29% | 3.11M | $66.77M |
| 7 | Blackrock Inc. | 4.69% | 2.31M | $49.75M |
| 8 | Vanguard Capital Management LLC | 3.64% | 1.80M | $38.63M |
| 9 | Baker Bros. Advisors, LP | 3.32% | 1.64M | $35.28M |
| 10 | Remedium Capital Partners, LLC | 3.20% | 1.58M | $33.92M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for JBIO
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNS2Q2VnBObkhxU3BndnRlekh3enItb2tPZEhIMXJsNDc5d0d0dGNPMHJSd3RRWkpCdWROVFVQUFExLUo4bi1sb2ZnX0N4aW44djlGUmQ2Z0RzeHpBZHg2c1hNWUd2Y2lvUDNMMUQzWmRiVndLVUJpVVdqVk9zYm40MXVpUnlXZnVwbVlWNH…
Janus Henderson holds 6.27M JBIO shares, reporting 10.6% stake (JBIO) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQX0FhVjMwMlRORHBDb2dabDFuaEdiLTYzaHdSUzcwc1lrV2tEOHVhX2Uzd0NXV09SbGVveERXY0wyU2RKSFh0UWpRMFZpUWdLS1V1T1FrMHFPUmpDeVVQdEhjc2pIdTJUcEdhSHdrOFhTdmxQWXo0clBES0gxMUdTeXViTzE1QWZqT0QyVl…
Price to earnings forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQaEZYZ1lBRVJOZW1ndkRSZlpmTDl2NTR5UHN2YW9memhQLXRDaWt2d2hnMFhDNjdkZFhPdGRUeDN2dUY1ekRFYi1OcmVVc2FQX3BkQlNmeTgtdDRjQ19YZUNlaTkxR3NSVlNHSmlwWXhyRVJDLVpVMXFUNFlTN1FpbXZabTNmMzZ5T01hMj…
Jade Biosciences (JBIO) Joins Growth Indexes, Is The Stock Still Undervalued? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQaWMzaUhhWEVnaVRQSjBUQ2pvSDV4VWlHNmRMXzJsalc3cnV0NEtEc3dTbzdzUnZTSEQ3cGVodTF5bW5acHBmdUZfNUlIQmRMYi1nZnplaEkyb01hLWl3U2ZUU0tpRXlndmhoU3J0QTFmMkZnUURiWWZiLXBhb0ZQSzBEVUp2NTlmWlV1RE…
Jade Biosciences: Strong Early Signal, But Still A Wait For Proof (NASDAQ:JBIO) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPaHRnR0xyd1lNaVJ2cmhXSXluakZyS0lSRE5IZVI2eFFFbG9GcEVLUEhmWEFRR0RXbnBuUHdFMVZDeHFOSEE0ZTlGRE9yaHhQN05obUZsbHpxQkp5V25mV1NRcjVHTFFlWGpKYlR2LWRsZ20tQjJlOHhLU1JmU1M1RXF4LXBwRE40bGdYUV…
Jade Biosciences, Inc.(NasdaqCM: JBIO) added to S&P Biotechnology Select Industry Index - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPUlY2Z0QzUjlKaEd6Zm1vTHR4aWFiVWJFcmtxYzE0ZGc2X1BWSUN1VTZyUG5zNm9ELTE2TFhvcmJTLVhyRjJmdWotOXhqU28yYUVGQ2JvNFJ3NGM1TkYycWpHZlo3Sk00aTIxMkJ5Zm8yR3o1X2M3Wi1lQTB0cHNzekI4cm5lSlRfTThScm…
JBIO — Frequently Asked Questions
What is the current share price of Jade Biosciences, Inc. (JBIO)?
As of 2026-07-14 21:23 PDT, Jade Biosciences, Inc. (JBIO) trades at $21.34 on NasdaqCM. Its 52-week range is $6.77 to $26.85.
What is the market capitalisation of JBIO?
Jade Biosciences, Inc. (JBIO) has a market capitalisation of $1.30B on NasdaqCM.
What is the P/E ratio of JBIO?
JBIO trades at a trailing price-to-earnings (P/E) ratio of -8.11. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.55.
What is the return on equity (ROE) of JBIO?
JBIO has a return on equity (ROE) of -38.32%. Its return on capital employed (ROCE) is -34.07%.
Is JBIO a good stock to buy?
This page provides a data-driven analysis of Jade Biosciences, Inc. (JBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.